Mayo Clinic researchers have developed milk-derived nanoparticles to deliver treatment directly to cholangiocarcinoma tumors [1, 2].
This development addresses a critical gap in oncology for patients with bile-duct cancer. Because cholangiocarcinoma is rare and aggressive, it typically offers limited treatment options for those diagnosed [1].
The research, which emerged in March 2026 [1], focuses on using these specialized nanoparticles as a vehicle for therapy. By targeting the tumors directly, the system aims to increase the efficacy of the treatment while potentially reducing the systemic impact on the rest of the body [1, 2].
Dr. Rory L. Smoot, a hepatobiliary and pancreas surgeon at Mayo Clinic, is involved in the effort [3]. The project also connects with patient advocacy through Melinda Bachini, a survivor of the disease and the chief patient officer at the Cholangiocarcinoma Foundation [3].
The study was conducted at the Mayo Clinic facilities in Rochester, Minnesota [2, 3]. The goal is to create a more aggressive yet precise therapeutic approach for a cancer that has historically been difficult to treat [1].
By utilizing milk-derived components, the researchers are exploring how biological materials can be repurposed to navigate the body's defenses and reach malignant cells. This approach seeks to overcome the barriers that often prevent standard chemotherapy from reaching bile-duct tumors effectively [1, 2].
“Mayo Clinic researchers have developed milk-derived nanoparticles to deliver treatment directly to cholangiocarcinoma tumors.”
The use of milk-derived nanoparticles represents a shift toward 'biomimetic' drug delivery, where natural substances are used to trick the immune system into allowing medication to reach a tumor. If successful, this could provide a blueprint for treating other rare, hard-to-reach cancers that do not respond well to traditional systemic chemotherapy.
